Competing interests
D.M., A.M., A.H. owns stock
D.F., J.F., M.P.F., D.M., A.M., H.M.E.S., H.J., N.D.-R., D.B., Y.F., and M.M. have no competing interests to declare. M.P.O. is an employee, has stock options, a patent pending, and license and royalties with Regeneron Pharmaceuticals, Inc. G.A.H. is an employee and shareholder of Regeneron and is listed on pending patents for the REGEN-COV antibody cocktail. A.H. owns stock in Regeneron and Pfizer. K.-C.C. and E.F.-N. are employees and shareholders of Regeneron. K.C.T. and F.I. are employees and shareholders of Regeneron and are listed on a pending patent. L.R.B. is the Deputy Editor for the New England Journal of Medicine and has grants from the Bill and Melinda Gates Foundation, Harvard Medical School, the National Institutes of Health, and the Wellcome Trust. J.M. is an employee of and has stock options and stock grants from Moderna. H.Z. is an employee of and has stock options from Moderna. W.D. is an employee of Moderna. P.G.B. will be serving as an unpaid advisor on Moderna’s Zika Vaccine Advisory Board. M.S.C. serves on the scientific advisory boards of Aerium, ModexX, and Atea and has consulting roles with Astra Zenica and GSK.